Llovet, Josep M. http://orcid.org/0000-0003-0547-2667
Pinyol, Roser
Kelley, Robin K.
El-Khoueiry, Anthony
Reeves, Helen L.
Wang, Xin Wei
Gores, Gregory J.
Villanueva, Augusto http://orcid.org/0000-0003-3585-3727
Article History
Received: 27 September 2021
Accepted: 25 February 2022
First Online: 28 April 2022
Competing interests
: J.M.L. received research support from Bayer HealthCare Pharmaceuticals, Eisai, Boehringer Ingelheim and Ipsen and consulting fees from Merck, Eli Lilly, Eisai, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Ipsen, Genentech, Roche, Glycotest, Nucleix, Omega Therapeutics, Iylon, Mina Alpha, Boston Scientific and AstraZeneca. H.L.R. has acted in an advisory capacity for Boston Scientific and Sirtex, and received speaker fees from Eisai and Bayer. A.V. has received consulting fees from Boehringer Ingelheim, FirstWorld, Natera, Cambridge Healthcare Research and Genentech; advisory board fees from Bristol Myers Squibb, Gilead and NGM Pharmaceuticals; and research support from Eisai. R.K.K. received research support from Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Exelixis, Genentech–Roche, Merck, Partner Therapeutics, Novartis, QED, Relay Therapeutics, Surface Oncology and Taiho; and consulting and/or advisory fees from Exact Sciences, Genentech–Roche and Gilead. A.E.-K. has received research support from Astex, AstraZeneca and Fulgent; advisory or consulting fees from Bayer, Bristol Myers Squibb, Eisai, Merck, Exelixis, AstraZeneca, Roche–Genentech, Agenus, ABL Bio, QED, Gilead, CytomX, Pieris and EMD Serono. G.J.G., X.W.W. and R.P. have no competing interests.